Literature DB >> 12559287

Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy.

Mohamed A Elshaikh1, Kenneth Angermeier, James C Ulchaker, Eric A Klein, Mark A Chidel, Stephen Mahoney, D Allan Wilkinson, Chandana A Reddy, Jay P Ciezki.   

Abstract

OBJECTIVES: To correlate anatomic, procedural, and dosimetric parameters with the rate of intermittent self-catheterization (ISC).
METHODS: The records of 402 patients with a median age of 69 years treated with 125I prostate seed implantation from 1996 to 2001 were reviewed for the use of ISC. The records were examined for the preimplant factors: prostate volume, use of androgen deprivation, and prostate length. The intraprocedural factor reviewed was the number of needles used. The following postimplant information was also collected: preimplant transrectal ultrasound-generated prostate volume/postimplant computed tomography-generated prostate volume ratio, V100, V150, V200, V300, V400, D90, and D100. Correlation was assessed using logistic regression analysis.
RESULTS: Forty-four patients had to use ISC (10.9%). The mean and median duration of ISC was 11.9 and 6 weeks, respectively. From univariate analysis, prostate length and prostate volume were found to be statistically significant predictors of ISC after 125I prostate seed implantation with a P value of 0.0002 and 0.0042, respectively. With multivariate analysis, only prostate length was a statistically significant predictor of ISC use after 125I prostate seed implantation (P = 0.0095).
CONCLUSIONS: Prostate length is an important predictor of ISC after 125I prostate seed implantation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559287     DOI: 10.1016/s0090-4295(02)02142-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Comparison of urethral diameters for calculating the urethral dose after permanent prostate brachytherapy.

Authors:  Osamu Tanaka; Shinya Hayashi; Masayuki Matsuo; Masahiro Nakano; Yasuaki Kubota; Sunaho Maeda; Kazuhiro Ohtakara; Takashi Deguchi; Hiroaki Hoshi
Journal:  Radiat Med       Date:  2007-08-27

2.  Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study.

Authors:  Nobutaka Shimizu; Takafumi Minami; Koichi Sugimoto; Yoshitaka Saito; Yutaka Yamamoto; Taiji Hayashi; Hidenori Tsuji; Masahiro Nozawa; Kazuhiro Yoshimura; Tokumi Ishii; Hirotsugu Uemura; Kiyoshi Nakamatsu
Journal:  World J Urol       Date:  2014-01-17       Impact factor: 4.226

Review 3.  Prostate brachytherapy for localized prostate cancer.

Authors:  Jay P Ciezki
Journal:  Curr Treat Options Oncol       Date:  2005-09

Review 4.  Permanent interstitial brachytherapy for prostate cancer: a current review.

Authors:  Jeffrey Woolsey; Nicole Miller; Dan Theodorescu
Journal:  World J Urol       Date:  2003-08-13       Impact factor: 4.226

5.  Influence of zonal dosimetry on prostate brachytherapy outcomes.

Authors:  Cheng William Hong; Chandana A Reddy; D Allan Wilkinson; Eric A Klein; Jay P Ciezki
Journal:  J Contemp Brachytherapy       Date:  2015-02-04

6.  Prostate brachytherapy in Ghana: our initial experience.

Authors:  James Edward Mensah; Joel Yarney; Verna Vanderpuye; Evans Akpakli; Samuel Tagoe; Evans Sasu
Journal:  J Contemp Brachytherapy       Date:  2016-10-11

7.  Prophylactic urethral stenting with Memokath® 028SW in prostate cancer patients undergoing prostate 125I seed implants: phase I/II study.

Authors:  Samuel T Chao; Kenneth Angermeier; Eric A Klein; Chandana A Reddy; James C Ulchaker; Andrew Stephenson; Steven Campbell; Jay P Ciezki
Journal:  J Contemp Brachytherapy       Date:  2011-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.